Zusammenfassungen der Arbeiten (Abstracts NIR 2001)

Titel
Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes.

Autor
Bischof F., Wienhold W., Wirblich C., Malcherek G., Zevering O., Kruisbeek A.M., Melms A.

Quelle
Proc Natl Acad Sci U S A 2001 Oct 9;98(21):12168-73

Zusammenfassung
The invariant chain (Ii) binds to newly synthesized MHC class II molecules with the CLIP region of Ii occupying the peptide-binding groove. Here we demonstrate that recombinant Ii proteins with the CLIP region replaced by antigenic self-epitopes are highly efficient in activating and silencing specific T cells in vitro and in vivo. The Ii proteins require endogenous processing by antigen-presenting cells for efficient T cell activation. An Ii protein encompassing the epitope myelin basic protein amino acids 84-96 (Ii-MBP84-96) induced the model autoimmune disease experimental allergic encephalomyelitis (EAE) with a higher severity and earlier onset than the peptide. When applied in a tolerogenic manner, Ii-MBP84-96 abolished antigen-specific T cell proliferation and suppressed peptide-induced EAE more effectively than peptide alone. Importantly, i.v. administration of Ii proteins after EAE induction completely abrogated the disease, whereas peptides only marginally suppressed disease symptoms. Ii fusion proteins are thus more efficient than peptide in modulating CD4(+) T cell-mediated autoimmunity, documenting their superior qualities for therapeutic antigen delivery in vivo.

Abstract PubMed/Medline:

auf der Website: www.ncbi.nlm.nih.gov

Vollständiger Artikel (PNAS Online):

auf der Website: www.ncbi.nlm.nih.gov


© 2012 Deutsche Gesellschaft für Autoimmun-Erkrankungen e.V. [ Copyright im Impressum ]
Bitte beachten Sie unseren Haftungshinweis [ Haftungshinweis im Impressum]
Umsetzung: www.jn-designmedia.com

NIR 2012

Aktuelle Ausschreibung

NIR 2007/2008

Neues Tiermodell für die Autoimmun-Hepatitis des Menschen

NIR 2005/2006

Therapieansatz für bakteriell-induzierte Autoimmunerkrankungen

NIR 2003/2004

Erster klinischer Response-Marker für die Interferon-ß-Therapie bei Multipler Sklerose

NIR 2002

Neue Methode zur gezielten Unterdrückung des Immunsystems

NIR 2001

Neue Forschungsergebnisse zu Multipler Sklerose und Guillain-Barré-Syndrom

NIR 1999/2000

Neue Erkenntnisse beim Pemphigus vulgaris